<DOC>
	<DOCNO>NCT00729001</DOCNO>
	<brief_summary>This dose exploration study assess safety immunogenicity two dos candidate HRV vaccine different virus concentration target age group ( infant approximately 2 month age previously uninfected human rotavirus ) receive concomitant administration routine vaccination . The study also aim explore effect unrestricted feeding immunogenicity vaccine .</brief_summary>
	<brief_title>Study Two Doses GSK Biologicals ' Live Attenuated HRV Vaccine ( Two Different Formulations ) Healthy Infants .</brief_title>
	<detailed_description>All subject enrol Eastern United States Eastern Canada continue participation pilot efficacy follow-up ( pilot efficacy subset ) . The third dose IPV vaccine ( IPOL ) may give visit 3 , 4 another time , investigator 's discretion . Comvax may give place OmniHIB/ActHIB Visit 1 Visit 2 third dose Comvax administer accord prescribe information .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child , include 6 12 week ( 4290 day ) age time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject . Born normal gestation period ( 36 42 week ) . Use investigational nonregistered drug vaccine study vaccine within 30 day precede study vaccine placebo plan use study period . Planned administration vaccine ( include routine pediatric vaccine ) foresee study protocol period start 14 day dose vaccine ( ) end 14 day . Hepatitis B vaccine give concomitantly within 14 day vaccination exclusion criterion . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug since birth . History diphtheria , tetanus , pertussis , polio , Hib disease and/or invasive pneumococcal infection . History invasive pneumococcal infection exclusion criterion Canadian subject . Previous vaccination diphtheria , tetanus , pertussis , polio , Haemophilus influenzae type b , and/or Streptococcus pneumoniae . Previous vaccination Streptococcus pneumoniae exclusion criterion Canadian subject . Use antibiotic within 7 day precede dose 1 . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation GI tract serious medical condition determine investigator . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbated component vaccine . Acute disease time enrollment . Gastroenteritis within 7 day precede study vaccine administration . Household contact immunosuppressed individual pregnant woman . Administration immunoglobulins and/or blood product since birth plan administration study period . Previous confirm occurrence rotavirus gastroenteritis . Inability contact parents/guardians subject telephone .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Rotavirus Gastroenteritis</keyword>
	<keyword>Human rotavirus vaccine</keyword>
</DOC>